AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11268494 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (1000 mg/m2 day 1), epidoxorubicin (60 mg/m2 day 1), and vincristine (1.4 mg/m2 day 1) every 14 days for six cycles followed by cisplatin (40 mg/m2 days 1 & 2) and etoposide (100 mg/m2 days 1‐3) every 14 days for four cycles, with prophylactic filgrastim (300 mcg subcutaneously from day 5 to day 10)
Number of subjects: 16
Study 11268494 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, epidoxorubicin, and vincristine followed by cisplatin and etoposide
Number of subjects: 16
Study 9048699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with 'isumaluttuq' label
Number of subjects: 137
Study 9048699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with 'demon possession' label
Number of subjects: 137
Study 9048699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with 'mental illness' label
Number of subjects: 137
Study 9048699 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette behavior (threatening or withdrawn)
Number of subjects: 137
Study 9048699 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender, more education, less familiarity with behavior, perception of less likelihood of recovery
Number of subjects: 137
Study 7698963 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved technique for pleural drain insertion
Number of subjects: 0
Study 3235816 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg DZ MM i.v. + placebo i.m.
Number of subjects: 0
Study 3235816 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg DZ i.v. + placebo i.m.
Number of subjects: 0
Study 3235816 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg DZ MM i.m. + placebo i.v.
Number of subjects: 0
Study 3235816 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg DZ i.m. + placebo i.v.
Number of subjects: 0
Study 3235816 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.v. + placebo i.m.
Number of subjects: 0
Study 3235816 — intervention group
Group type: EXPERIMENTAL
Intervention: All active substances (DZ MM i.v., DZ i.v., DZ MM i.m., DZ i.m.)
Number of subjects: 0
Study 3235816 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ MM i.m.
Number of subjects: 0
Study 31278414 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocon‐700
Number of subjects: 50
Study 31278414 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 50
Study 28648567 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 27
Study 28648567 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 27
Study 26586042 — intervention group
Group type: EXPERIMENTAL
Intervention: Male players
Number of subjects: 66
Study 26586042 — intervention group
Group type: COMPARATOR
Intervention: Players with a history of ankle sprain
Number of subjects: 66
Study 26586042 — intervention group
Group type: COMPARATOR
Intervention: Players without a history of ankle sprain
Number of subjects: 66
Study 24716668 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg selenium-enriched yeast (SelenoPrecise®) daily for 12 months
Number of subjects: 472
Study 24716668 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets daily for 12 months
Number of subjects: 472
Study 23692173 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy
Number of subjects: 464
Study 23692173 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 464
Study 20617412 — intervention group
Group type: COMPARATOR
Intervention: MitraClip device
Number of subjects: 0
Study 20617412 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 18398972 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher breast milk viral load at 1 week, 1 month, and 4 months
Number of subjects: 138
Study 18398972 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated breast milk sodium concentration (> or =13 mmol/L) at 4 months
Number of subjects: 138
Study 18398972 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated sodium concentration at 1 week postpartum
Number of subjects: 138
Study 18398972 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent viral shedding and high breast milk viral load
Number of subjects: 138
Study 18398972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium concentrations later in breast-feeding
Number of subjects: 138
Study 16618589 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised and structured nursing intervention with education
Number of subjects: 0
Study 16618589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nursing intervention)
Number of subjects: 0
Study 14666354 — intervention group
Group type: EXPERIMENTAL
Intervention: Triancinolone 10 mg/ml intralesional injection
Number of subjects: 14
Study 14666354 — intervention group
Group type: COMPARATOR
Intervention: Saline solution 0.9% injection (placebo)
Number of subjects: 14
Study 10995093 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-based surgery
Number of subjects: 56
Study 10995093 — intervention group
Group type: COMPARATOR
Intervention: Health centre-based surgery
Number of subjects: 56
Study 7943838 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.75% (6-8 ml)
Number of subjects: 20
Study 7943838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bupivacaine (1.2 mg.min-1)
Number of subjects: 20
Study 7943838 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (6-8 ml)
Number of subjects: 20
Study 3036980 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical drops containing combinations of antibiotics and steroids (including one with an anti-fungal agent)
Number of subjects: 27
Study 3036980 — intervention group
Group type: COMPARATOR
Intervention: Boric acid in spirit
Number of subjects: 27
Study 31044759 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (15.2 g/day) after a low-salt diet (2.9 g/day) for 7 days each
Number of subjects: 374
Study 31044759 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (15.2 g/day)
Number of subjects: 374
Study 31044759 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of extra salt
Number of subjects: 374
Study 27634780 — intervention group
Group type: EXPERIMENTAL
Intervention: Kin Keeper(SM) cancer prevention intervention delivered by community health workers (CHWs) via existing community programs
Number of subjects: 0
Study 24261345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine-sevoflurane (Group N)
Number of subjects: 62
Study 24261345 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-sevoflurane (Group R)
Number of subjects: 62
Study 24261345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-sevoflurane (Group D)
Number of subjects: 62
Study 22486470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Balanced Occlusion (BBO)
Number of subjects: 44
Study 22486470 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine Guidance (CG)
Number of subjects: 44
Study 20796315 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabinogalactan extract (ResistAid™)
Number of subjects: 45
Study 20796315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18097227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily plus two nucleoside reverse transcriptase inhibitors
Number of subjects: 21
Study 18097227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily
Number of subjects: 21
Study 16882678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CoQ(10) (100 mg tid)
Number of subjects: 23
Study 16882678 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) (60% of peak VO(2), five times a week)
Number of subjects: 23
Study 16882678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16882678 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ET
Number of subjects: 23
Study 16882678 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) plus ET
Number of subjects: 23
Study 14714358 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangya Capsule (JYC)
Number of subjects: 35
Study 14714358 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (Control)
Number of subjects: 35
Study 10813709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy consisting of intraarterial cisplatin infusion (2 mg/kg every 8 weeks) and systemic interferon-alpha (3 million IU/m2 subcutaneously 3 times a week)
Number of subjects: 68
Study 10813709 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial cisplatin infusion (2 mg/kg every 8 weeks)
Number of subjects: 68
Study 10813709 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 68
Study 10813709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha
Number of subjects: 68
Study 10813709 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial cisplatin infusion
Number of subjects: 68
Study 8782256 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neomycin, polymyxin B, and dexamethasone
Number of subjects: 108
Study 8782256 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 108
Study 1738550 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 0
Study 1738550 — intervention group
Group type: COMPARATOR
Intervention: General conditioning exercises
Number of subjects: 0
Study 1738550 — intervention group
Group type: COMPARATOR
Intervention: Vestibular suppressant medication
Number of subjects: 0
Study 6675729 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter presence
Number of subjects: 53
Study 6675729 — intervention group
Group type: COMPARATOR
Intervention: Experimenter absence
Number of subjects: 53
Study 31787595 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0
Study 31787595 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study 31787595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30572991 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (insulin treatment only)
Number of subjects: 46
Study 26305613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 63
Study 24271142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg daily
Number of subjects: 71
Study 22714138 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG feedback (N = 21)
Number of subjects: 46
Study 22714138 — intervention group
Group type: COMPARATOR
Intervention: Control group with video recording (N = 25)
Number of subjects: 46
Study 21073054 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (300 mg) + Doxycycline (200 mg)
Number of subjects: 44
Study 21073054 — intervention group
Group type: COMPARATOR
Intervention: DEC (300 mg) + Placebo
Number of subjects: 44
Study 17917553 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 2227
Study 17917553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2227
Study 16330719 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (n = 906)
Number of subjects: 1801
Study 16330719 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (n = 895)
Number of subjects: 1801
Study 16330719 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Number of subjects: 1801
Study 11895065 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogs (bimatoprost, latanoprost, travoprost)
Number of subjects: 0
Study 11895065 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone
Number of subjects: 0
Study 11895065 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogs
Number of subjects: 0
Study 10646748 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacle correction for early-onset refractive accommodative esotropia
Number of subjects: 43
Study 10646748 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical onset after 2 years old)
Number of subjects: 43
Study 10646748 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurity as a risk factor
Number of subjects: 43
Study 7667331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold environment at 5 degrees C (CT)
Number of subjects: 0
Study 7667331 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT1A agonist ipsapirone (IPS)
Number of subjects: 0
Study 7667331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC) at 28 degrees C
Number of subjects: 0
Study 2497632 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 16
Study 2497632 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented-then-pasteurized milk (FPM)
Number of subjects: 16
Study 658012 — intervention group
Group type: EXPERIMENTAL
Intervention: Metapramine (19560 R.P.)
Number of subjects: 0
Study 658012 — intervention group
Group type: COMPARATOR
Intervention: Clorimipramine
Number of subjects: 0
Study 30945802 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 247
Study 30945802 — intervention group
Group type: COMPARATOR
Intervention: Traditional pathway
Number of subjects: 247
Study 28002105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery with more-aggressive freezing techniques
Number of subjects: 0
Study 28002105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery with less-aggressive freezing techniques
Number of subjects: 0
Study 28002105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery on the scalp
Number of subjects: 0
Study 28002105 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with ingenol mebutate gel, 0.015% after 3 weeks
Number of subjects: 0
Study 28002105 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with vehicle gel after 3 weeks
Number of subjects: 0
Study 26186553 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of patient-physician care planning discussions within one month of metastatic diagnosis
Number of subjects: 665
Study 26186553 — intervention group
Group type: COMPARATOR
Intervention: No documentation of patient-physician care planning discussions
Number of subjects: 665
Study 23391319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 32
Study 23391319 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 32
Study 21181475 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (100 mg/m², 1-hour infusion, weekly for 6 weeks)
Number of subjects: 74
Study 19097797 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged orthoses
Number of subjects: 66
Study 19097797 — intervention group
Group type: COMPARATOR
Intervention: Neutral orthotic group (control)
Number of subjects: 66
Study 19097797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Laterally wedged orthoses and Neutral orthotic)
Number of subjects: 66
Study 16990723 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOS
Number of subjects: 53
Study 15149512 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 cream applied twice daily for 8 weeks
Number of subjects: 49
Study 15149512 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 8 weeks
Number of subjects: 49
Study 15149512 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 cream
Number of subjects: 49
Study 15149512 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 49
Study 10828706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping of the membranes
Number of subjects: 104
Study 10828706 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine stimulation with oxytocin
Number of subjects: 104
Study 10828706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Codfish
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Mackerel
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Herring
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaice
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine release test
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE tests
Number of subjects: 38
Study 9048527 — intervention group
Group type: COMPARATOR
Intervention: Maxisorp RAST
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of the codfish Maxisorp RAST
Number of subjects: 38
Study 9048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-reactivity to shrimp or milk
Number of subjects: 38
Study 8392210 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (beta 1, beta 2, and beta 3-agonist)
Number of subjects: 0
Study 8392210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg (beta 1/beta 2 antagonist)
Number of subjects: 0
Study 8392210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 5 mg (beta 1/beta 2 antagonist)
Number of subjects: 0
Study 8392210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg (beta 1 antagonist)
Number of subjects: 0
Study 2881423 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (d‐Tc) 50 micrograms/kg + alfentanil (Alf) 20 micrograms/kg
Number of subjects: 80
Study 2881423 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine (d‐Tc) 50 micrograms/kg + alfentanil (Alf) 50 micrograms/kg
Number of subjects: 80
Study 2881423 — intervention group
Group type: EXPERIMENTAL
Intervention: Alf 10 micrograms/kg + Alf 20 micrograms/kg
Number of subjects: 80
Study 2881423 — intervention group
Group type: EXPERIMENTAL
Intervention: Alf 10 micrograms/kg + Alf 50 micrograms/kg
Number of subjects: 80
Study 2881423 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose alfentanil groups
Number of subjects: 80
Study 2881423 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 29878062 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB + SN
Number of subjects: 5290
Study 29878062 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB + NRT
Number of subjects: 5290
Study 29878062 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB + SN + NRT
Number of subjects: 5290
Study 29878062 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB
Number of subjects: 5290
Study 26787203 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD promoting breast cancer awareness
Number of subjects: 2
Study 26787203 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2
Study 24296871 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (200 mg/day) for 3 months
Number of subjects: 70
Study 24296871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24296871 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 70
Study 22751025 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga of Awareness intervention (8-week duration)
Number of subjects: 39
Study 22751025 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice rates
Number of subjects: 39
Study 20483519 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5min DVD without practice
Number of subjects: 396
Study 20483519 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5min DVD with manikin practice
Number of subjects: 396
Study 20483519 — intervention group
Group type: EXPERIMENTAL
Intervention: 9min DVD with manikin practice and scenario training
Number of subjects: 396
Study 20483519 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario training
Number of subjects: 396
Study 20483519 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 396
Study 18613385 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemopressin (1 mg tri‐glycyl‐lysin‐vasopressin acetate, 2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Number of subjects: 41
Study 18613385 — intervention group
Group type: COMPARATOR
Intervention: Glypressin (2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Number of subjects: 41
Study 18613385 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemopressin
Number of subjects: 41
Study 18613385 — intervention group
Group type: COMPARATOR
Intervention: Glypressin
Number of subjects: 41
Study 18613385 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemopressin and Glypressin
Number of subjects: 41
Study 16636120 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly (OW) alendronate 70 mg
Number of subjects: 833
Study 16636120 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly (OW) risedronate 35 mg
Number of subjects: 833
Study 14645423 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 127
Study 11080325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed smoking cessation and relapse prevention intervention
Number of subjects: 140
Study 8827792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 32
Study 8827792 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (0.5 mg/kg)
Number of subjects: 32
Study 8827792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1426825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (666 mg, 2 tablets)
Number of subjects: 24
Study 1426825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 4059470 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 36
Study 4059470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29168022 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst stage transfer
Number of subjects: 388
Study 29168022 — intervention group
Group type: COMPARATOR
Intervention: Cleavage stage transfer
Number of subjects: 388